Pseudoprogression in Non–Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?

Roberto Ferrara; Caroline Caramella; Benjamin Besse; Stéphane Champiat

doi:10.1016/j.jtho.2018.12.011

Pseudoprogression in Non–Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?

Roberto Ferrara, Caroline Caramella, Benjamin Besse, Stéphane Champiat

Research output: Contribution to journal › Editorial

32 Citations (Scopus)

Original language	English
Pages (from-to)	328-331
Number of pages	4
Journal	Journal of Thoracic Oncology
Volume	14
Issue number	3
DOIs	https://doi.org/10.1016/j.jtho.2018.12.011
Publication status	Published - 1 Mar 2019

Access to Document

10.1016/j.jtho.2018.12.011

Cite this

@article{5ccadd4e18aa4fe29d7e9a10387ff430,

title = "Pseudoprogression in Non–Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?",

author = "Roberto Ferrara and Caroline Caramella and Benjamin Besse and St{\'e}phane Champiat",

note = "Funding Information: Disclosure: Dr. Champiat has received honoraria from Amgen, AstraZeneca, BMS, Janssen, MSD, Novartis, and Roche. As part of the Drug Development Department of Institut Gustave Roussy, Dr. Champiat is subinvestigator of clinical trials for AbbVie, Agios Pharmaceuticals, Amgen, Argen-X BVBA, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Aveo, Bayer Healthcare AG, BBB Technologies B.V., Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Chugai Pharmaceutical Co., Clovis Oncology, Daiichi Sankyo, Debiopharm S.A., Eisai, Eli Lilly and Company, Exelixis, Forma, Gamamabs, Genentech, Inc., GlaxoSmithKline, H3 Biomedicine, Inc., Hoffmann La Roche AG, Innate Pharma, Iris Servier, Janssen Cilag, Kyowa Kirin Pharmaceutical Development, Inc., Loxo Oncology, Lytix Biopharma AS, Medimmune, Menarini Ricerche, Merck Sharp and Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology NV, Oncoethix, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Pfizer, Pharma Mar, Pierre Fabre, Roche, Sanofi Aventis, Taiho Pharma, Tesaro, Inc., and Xencor. Also as part of the Drug Development Department of Institut Gustave Roussy, Dr. Champiat has received research grants from AstraZeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, and Sanofi and nonfinancial support (drugs supplied) from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Johnson and Johnson, Eli Lilly and Company, Medimmune, Merck, NH TherAGuiX, Pfizer, and Roche. Dr. Besse reports performing research at Institut Gustave Roussy that was sponsored by AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly and Company, GSK, Ignyta, IPSEN, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, PharmaMar SA, Sanofi, Spectrum Pharmaceuticals, Takeda, and Tiziana Pharma outside the submitted work. The remaining authors declare no conflict of interest.",

year = "2019",

month = mar,

day = "1",

doi = "10.1016/j.jtho.2018.12.011",

language = "English",

volume = "14",

pages = "328--331",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

number = "3",

}

TY - JOUR

T1 - Pseudoprogression in Non–Small Cell Lung Cancer upon Immunotherapy

T2 - Few Drops in the Ocean?

AU - Ferrara, Roberto

AU - Caramella, Caroline

AU - Besse, Benjamin

AU - Champiat, Stéphane

N1 - Funding Information: Disclosure: Dr. Champiat has received honoraria from Amgen, AstraZeneca, BMS, Janssen, MSD, Novartis, and Roche. As part of the Drug Development Department of Institut Gustave Roussy, Dr. Champiat is subinvestigator of clinical trials for AbbVie, Agios Pharmaceuticals, Amgen, Argen-X BVBA, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca, Aveo, Bayer Healthcare AG, BBB Technologies B.V., Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Chugai Pharmaceutical Co., Clovis Oncology, Daiichi Sankyo, Debiopharm S.A., Eisai, Eli Lilly and Company, Exelixis, Forma, Gamamabs, Genentech, Inc., GlaxoSmithKline, H3 Biomedicine, Inc., Hoffmann La Roche AG, Innate Pharma, Iris Servier, Janssen Cilag, Kyowa Kirin Pharmaceutical Development, Inc., Loxo Oncology, Lytix Biopharma AS, Medimmune, Menarini Ricerche, Merck Sharp and Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Nanobiotix, Nektar Therapeutics, Novartis Pharma, Octimet Oncology NV, Oncoethix, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Pfizer, Pharma Mar, Pierre Fabre, Roche, Sanofi Aventis, Taiho Pharma, Tesaro, Inc., and Xencor. Also as part of the Drug Development Department of Institut Gustave Roussy, Dr. Champiat has received research grants from AstraZeneca, BMS, Boehringer Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, and Sanofi and nonfinancial support (drugs supplied) from AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Johnson and Johnson, Eli Lilly and Company, Medimmune, Merck, NH TherAGuiX, Pfizer, and Roche. Dr. Besse reports performing research at Institut Gustave Roussy that was sponsored by AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly and Company, GSK, Ignyta, IPSEN, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, PharmaMar SA, Sanofi, Spectrum Pharmaceuticals, Takeda, and Tiziana Pharma outside the submitted work. The remaining authors declare no conflict of interest.

PY - 2019/3/1

Y1 - 2019/3/1

UR - http://www.scopus.com/inward/record.url?scp=85061631538&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2018.12.011

DO - 10.1016/j.jtho.2018.12.011

M3 - Editorial

C2 - 30782378

AN - SCOPUS:85061631538

SN - 1556-0864

VL - 14

SP - 328

EP - 331

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 3

ER -

Pseudoprogression in Non–Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?

Access to Document

Other files and links

Cite this